A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support

A three-arm randomized controlled non-inferiority pilot study comparing anticoagulation strategies using unfractionated heparin, argatroban and enoxaparin for extracorporeal membrane oxygenation support conducted as an investigator-initiated, prospective, parallel group, open-label, active comparator controlled, single center, phase IV study to evaluate the non-inferiority of enoxaparin or argatroban for anticoagulation during ECMO therapy in comparison to the current standard, unfractionated heparin, as measured by the incidence of thromboembolic events during the duration of ECMO therapy

Start Date30 Jul 2024

Sponsor / Collaborator

Medical University of Vienna

EUCTR2022-002259-20-AT / Unknown statusPhase 4IIT

A three-arm randomized controlled non-inferiority pilot study Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Membrane Oxygenation support - CASUAL ECMO Trial

Start Date17 Aug 2023

Sponsor / Collaborator

Medical University of Vienna

NCT05226442 / CompletedPhase 2/3IIT

A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)

This prospective, randomized, controlled pilot trial aims to assess the safety and feasibility of Argatroban as an alternative anticoagulant to unfractionated heparin in patients receiving extracorporeal membrane oxygenation.

Start Date01 Dec 2021

Sponsor / Collaborator

Medical University of Vienna

100 Clinical Results associated with Argatroban

100 Translational Medicine associated with Argatroban

100 Patents (Medical) associated with Argatroban

1,592

Literatures (Medical) associated with Argatroban

01 Oct 2024·UROLOGY

Implementation of Robot-assisted Urologic Surgeries Using Hugo RAS System in a High-volume Robotic “Da Vinci Xi” Center: Outcomes and Initial Experience

Article

Author: Duarte, Ivan Kirche ; Pereira, Hernestina Mariana Jorge ; Kayano, Paulo Priante ; Lemos, Gustavo Caserta ; Lau, Clayton ; Teles, Saulo Borborema ; Andrade, Guilherme Miranda ; Barbosa, Alan Roger Gomes ; Bianco, Bianca ; Gavassa, Fabiana Parreira ; Olivares, Ruben ; Carneiro, Arie

OBJECTIVE:

To describe the trocar disposition, docking angles, surgical times, functional outcomes, and complications experienced during the first 30 surgeries with Hugo RAS platform performed by a high-volume Da Vinci Xi's surgeon.

METHODS:

Retrospective, observational, descriptive study was performed between May-December 2023. Safety and feasibility of the procedures were evaluated considering console and docking time (minutes), perioperative complications (Clavien-Dindo classification), blood loss (mL), and collision of the arms during the procedures (Yes/No). For radical prostatectomies (RARP) the urinary continence and sexual function were also evaluated.

RESULTS:

RARP, simple prostatectomies (RASP), partial nephrectomies (RAPN), and cystectomy (RARC) were performed. Trocar placement, docking, and bed assistant ergonomics were important challenges. Patient positioning, trocar placement, and robotic arm positioning had to be adapted. The median console operative time for RARP and RASP was 78 (60-120) minutes and 79 (58-125) minutes, respectively. The median docking time for both RARP and RASP was 10 (5-20) minutes. Of patients undergoing RARP, 94.5% recovered sexual function and no patient used more than one PAD per day after 90days of the surgery. The median console operative and docking time for RAPN was 82 (80-130) minutes and 12 (7-19) minutes, respectively. Blood loss in all patients was less than 200 mL and all none procedure presented major complications.

CONCLUSION:

For a high-volume surgeon with motivated and well-trained multidisciplinary team, the implementation of HUGO RAS system for urological program is safe and smooth. Adaptations were necessary to achieve equivalent surgical technique and results. Docking position and bed assistant ergonomics are the major challenges.

15 Sep 2024·PHYTOCHEMICAL ANALYSIS

Screening thrombin inhibitors from Yangxinshi tablets by online capillary electrophoresis-based immobilized enzyme microreactor and molecular docking.

Article

Author: He, Jun ; Chang, Yanxu ; Li, Jin ; Yao, Yaqi ; Du, Kunze ; Liu, Wenping ; Wen, Jiake ; Zhou, Rui

INTRODUCTION:

Yangxinshi tablet (YXST) is a effective traditional Chinese medicine in treating cardiovascular diseases such as heart failure and myocardial infarction.

OBJECTIVES:

This study aims to develop a method for screening thrombin inhibitors from YXST using an online immobilized enzyme microreactor (IMER) based on capillary electrophoresis (CE).

MATERIALS AND METHODS:

Thrombin (THR) was immobilized on the capillary's inner wall using polydopamine (PDA). The chromogenic substrate S-2238 was employed to assess thrombin (THR) activity and kinetic parameters. The stability and repeatability of the constructed thrombin-immobilized enzyme microreactor (THR-IMER) were evaluated over 40 runs, maintaining 85% of initial activity. The Michaelis-Menten constant (K_m) for THR was determined to be 11.98 mM. The half-maximal inhibitory concentration (IC₅₀) and inhibition constant (K_i) for argatroban on THR were calculated. Ten compounds in YXST were screened for THR inhibitory potency using the THR-IMER.

RESULTS:

Salvianolic acid B and caffeic acid were identified as potential THR inhibitors in YXST, with inhibition rates at 200 μg/mL of 55.06 ± 6.70% and 31.88 ± 4.79%, respectively, aligning with microplate reader assay results. Molecular docking analysis confirmed their interactions with key THR residues, verifying their inhibitory activity.

CONCLUSION:

The CE-based THR-IMER method was successfully developed for screening thrombin inhibitors from YXST, offering a reliable approach for identifying potential therapeutic compounds.

05 Sep 2024·NEW ENGLAND JOURNAL OF MEDICINE

Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke

Article

Author: Grotta, James C ; Janis, Scott ; Broderick, Joseph ; Panagos, Peter ; Khatri, Pooja ; Pancioli, Arthur ; Berry, Scott ; Adeoye, Opeolu ; Hoffman, Melissa ; Ranasinghe, Tamra ; Wilson, Alastair ; Majjhoo, Aniel ; Ingles, James ; Sivakumar, Sanjeev ; Sabagha, Noor ; Streib, Christopher ; Levine, Steven R ; Barreto, Andrew D ; Yoo, Albert J ; Elm, Jordan ; Barsan, William ; Bentho, Oladi ; Jasne, Adam S ; Graves, Todd ; Demel, Stacie ; Huang, Josephine ; Vagal, Achala ; Pizzella, Stephanie ; Wintermark, Max ; Concha, Mauricio ; Gentile, Nina ; Davis, Iris ; Derdeyn, Colin P

BACKGROUND:

Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear.

METHODS:

We conducted a phase 3, three-group, adaptive, single-blind, randomized, controlled clinical trial at 57 sites in the United States. Patients with acute ischemic stroke who had received intravenous thrombolysis within 3 hours after symptom onset were assigned to receive intravenous argatroban, eptifibatide, or placebo within 75 minutes after the initiation of thrombolysis. The primary efficacy outcome, the utility-weighted 90-day modified Rankin scale score (range, 0 to 10, with higher scores reflecting better outcomes), was assessed by means of centralized adjudication. The primary safety outcome was symptomatic intracranial hemorrhage within 36 hours after randomization.

RESULTS:

A total of 514 patients were assigned to receive argatroban (59 patients), eptifibatide (227 patients), or placebo (228 patients). All the patients received intravenous thrombolysis (70% received alteplase, and 30% received tenecteplase), and 225 patients (44%) underwent endovascular thrombectomy. At 90 days, the mean (±SD) utility-weighted modified Rankin scale scores were 5.2±3.7 with argatroban, 6.3±3.2 with eptifibatide, and 6.8±3.0 with placebo. The posterior probability that argatroban was better than placebo was 0.002 (posterior mean difference in utility-weighted modified Rankin scale score, -1.51±0.51) and that eptifibatide was better than placebo was 0.041 (posterior mean difference, -0.50±0.29). The incidence of symptomatic intracranial hemorrhage was similar in the three groups (4% with argatroban, 3% with eptifibatide, and 2% with placebo). Mortality at 90 days was higher in the argatroban group (24%) and the eptifibatide group (12%) than in the placebo group (8%).

CONCLUSIONS:

In patients with acute ischemic stroke treated with intravenous thrombolysis within 3 hours after symptom onset, adjunctive treatment with intravenous argatroban or eptifibatide did not reduce poststroke disability and was associated with increased mortality. (Funded by the National Institute of Neurological Disorders and Stroke; MOST ClinicalTrials.gov number, NCT03735979.).

News (Medical) associated with Argatroban

06 Sep 2024

·www.drugs.com

Adjunctive IV Argatroban, Eptifibatide Do Not Cut Disability After Stroke

FRIDAY, Sept. 6, 2024 -- Adjunctive treatment with intravenous argatroban or eptifibatide does not reduce poststroke disability among patients with acute ischemic stroke treated with intravenous thrombolysis within three hours after symptom onset, according to a study published in the Sept. 5 issue of the New England Journal of Medicine . Opeolu Adeoye, M.D., from Washington University in St. Louis, and colleagues conducted a phase 3, randomized, controlled clinical trial at 57 U.S. sites involving patients with acute ischemic stroke who had received intravenous thrombolysis within three hours after symptom onset. Participants received intravenous argatroban (59 patients), eptifibatide (227 patients), or placebo (228 patients) within 75 minutes after initiation of thrombolysis. The researchers found that at 90 days, the mean utility-weighted modified Rankin scale scores were 5.2 ± 3.7, 6.3 ± 3.2, and 6.8 ± 3.0 with argatroban, eptifibatide, and placebo, respectively. The posterior probabilities that argatroban was better than placebo and that eptifibatide was better than placebo were 0.002 and 0.041, respectively (posterior mean difference in utility-weighted modified Rankin scale score, −1.51 ± 0.51 and −0.50 ± 0.29, respectively). The three groups had a similar incidence of symptomatic intracranial hemorrhage (4, 3, and 2 percent, respectively). Mortality at 90 days was higher in the argatroban and eptifibatide groups versus the placebo group (24 and 12 percent, respectively, versus 8 percent). "We found no benefit of adjunctive intravenous argatroban or eptifibatide in patients with acute ischemic stroke treated with intravenous thrombolysis within three hours after symptom onset," the authors write. Several authors disclosed ties to the biopharmaceutical industry.

Clinical ResultPhase 3

16 Jul 2024

·www.prnewswire.com

Benzodiazepine Drugs Market to Reach US$ 3.2 Billion by 2034, Growing at 3.5% CAGR | Impact of Psychological Conditions and Aging Population - Reports TMR

Benzodiazepine drugs are vastly used as psychoactive drugs, which can be used to control seizures, alcohol withdrawal symptoms, and other issues related to the psychological conditions of a human being. With the activity of drugs closely related to brain stimulation, the drug can act as a relaxant for muscles in the body. WILMINGTON, Del., July 16, 2024 /PRNewswire/ -- Owing to different governing factors, the development of the benzodiazepine drug market is expected to traverse a sluggish path of advancement during the forecasted period. With a CAGR of 3.5%, the industry will proceed to reach USD 3.2 billion by 2034. The last recorded size of the ecosystem was USD 2.2 billion in 2023. With the changing lifestyles and mounting pressures to cope with an accelerated pace of living, many people have been facing psychological issues. The growing prevalence of trauma, anxiety, mental fatigue, and many other psychological conditions is observed to have increased recently. To treat such medical conditions, an appropriate relaxant must be applied to get the desired results. This growing prevalence is a clear sign of an important driver that promises to elevate the size of the competitive space during the forecasted period. The rising geriatric population is contributing to the growing cases of insomnia. Along with the abovementioned factors, the growing senior population is trying to find solutions for issues like sleep deprivation. To cater to such issues, the use of benzodiazepine drugs is observed to have increased. Propel Your Business Success: Secure Your Sample of Our Latest Report Now! Due to the sedative properties of drugs, the use of such chemicals is observed to have gained traction in the case of muscle relaxants. To cater to such muscle spasms and other related issues, such drugs can be effective. This factor drives the sales of such drugs. With the spurring of innovation and growth in the technological infrastructure, product augmentation has become possible. Key players in the ecosystem invest more in innovation to alter formulations of drugs. This elevates drug delivery and response time, delivering better results. Rising investments in the pharmaceutical and healthcare industries have generated better prospects for leading organizations. As more market openings have been created in the industry, the scope of expanding the market increases for key players, benefitting the size of the industry. The growing research and development activities are expected to augment the drug efficacy and efficiency, which will likely benefit the industry. Due to this, such efforts have been fueling the industry's progress, creating opportunities for new entrants. Benzodiazepine Drugs Market Report Scope: Key Findings from the Market Report The competitive landscape of benzodiazepine drugs can be segmented into different categories depending on various parameters. Based on the drug type, Alprazolam is used to control anxiety issues. The drug controls an abnormal excitement in the brain. Based on the application segment, anxiety is the largest shareholder in the industry. Due to the changing lifestyle, such cases are increasing at an alarming rate, gaining more demand for the segment. Based on the time of use, various prolonged cases of such drugs are seen to have gained momentum. Curing deep psychological impacts is surging the demand for the segment. Based on the end-user, hospital pharmacies govern the largest market share due to better availability of drugs. Regional Profile The growing awareness of psychological health in Asia-Pacific is creating better prospects for the global benzodiazepine drug market. With the growing drug research activities in Europe, the demand for such drugs will likely increase due to a larger canvas. The progress of the healthcare and pharmaceutical industry in North America is a key factor in helping the region lead the global landscape. Competitive Landscape Among different firms expanding in the industry, Pfizer Inc. is a key player that produces different products to expand. Such products include aminophylline, etomidate, argatroban injection, and many more. UCB S.A. is another important player producing solutions for Briviact (brivaracetam) Epilepsy, Ankylosing spondylitis, and Myasthenia Gravis. Hikma Pharmaceuticals PLC operates in different verticals, including injectables, oral drugs, and other segments. Key Developments in the Benzodiazepine Drug Market In December 2023, Pfizer Inc. acquired Seagen. This move bolstered the position of the organization in the industry. In March 2024, UCB S.A. invested in IMIDomics, Inc. to innovate solutions for immune-mediated inflammatory diseases. This product launch helped the business augment products, bolstering the position in the market. Key Players Pfizer Inc. UCB S.A. Hikma Pharmaceuticals PLC Teva Pharmaceutical Industries Ltd. H.Lundbeck A/S Apotex Inc. Aurobindo Pharma Purdue Pharma Other Prominent Players Market Segmentation Drug Type Alprazolam Clonazepam Diazepam Lorazepam Others (Midazolam, etc.) Application Anxiety Insomnia Alcohol Withdrawal Seizures Others (Bipolar Disorder, etc.) Time of Action Ultra-short Acting Short Acting Long Acting End User Hospital Pharmacies Retail Pharmacies Online Pharmacies Region North America Europe Asia Pacific Latin America Middle East & Africa Drive Your Business Growth Strategy: Purchase the Report for Key Insights! Have a Look at Related Research Reports of Pharmaceutical Cardiovascular Drugs Market - The global cardiovascular drugs market, valued at USD 142.8 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2031. This growth trajectory is expected to elevate the market size to USD 195.6 billion by the end of 2031, driven by increasing prevalence of cardiovascular diseases, advancements in drug development, and rising healthcare expenditures globally. Insomnia Market - The global insomnia industry was worth US$ 3.8 billion in 2022. From 2023 to 2031, it is expected to increase at a CAGR of 6.0%, reaching US$ 6.4 billion. Various therapies have been explored for managing insomnia, offering non-pharmacological alternatives for those seeking sleep improvement. Bioengineered Protein Drugs Market - Rise in incidence of chronic diseases such as infectious diseases, autoimmune disorders, and cancer is a dominating factor contributing to the bioengineered protein drugs market growth. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Email: [email protected] Follow Us: LinkedIn | Twitter | Blog | YouTube Logo: SOURCE Transparency Market Research

Acquisition

17 Jun 2024

·www.prnewswire.com

ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE

SAINT-CLOUD, France, June 17, 2024 /PRNewswire/ -- Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), in Europe. Ethypharm, known for its expertise in essential drugs for central nervous system diseases (including severe pain and addiction) and hospital injectables, aims to strengthen its established pharmaceutical business in Europe through internal development, licensing and acquisitions. In Europe, MTPC first received approval for Argatroban in Sweden in 2004 and the product is currently available as a treatment for heparin-induced thrombocytopenia (HIT) type II in 13 countries, including Germany, the UK, France, Spain and Italy. Heparin induced thrombocytopenia (HIT) type II is a severe condition that carries the risk of fatal thromboembolic complications. Argatroban is an anticoagulant with a short half-life in the bloodstream that undergoes metabolism in the liver, making it suitable for patients post-surgery and those with kidney disease who may develop HIT type II. Denis Delval, CEO of Ethypharm, said: "We are delighted to strengthen our portfolio of essential drugs and bring Argatroban to patients in Europe. Furthermore, we are proud to take over this product following its originator, the well-recognized Mitsubishi Tanabe Pharma Corporation." About Ethypharm Ethypharm is a leading mid-sized international pharmaceutical company, with strong European roots, that manufactures and provides essential drugs, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine. Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment. Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations. The six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms. With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets. Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them. To find out more about Ethypharm, visit About Mitsubishi In Europe, MTPC's subsidiary, Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referred to as "MTPE," located in London, United Kingdom), and MTPE's subsidiary, Mitsubishi Tanabe Pharma GmbH (hereinafter referred to as "MTPD, located in Duesseldorf, Germany), have been actively involved in the marketing and sales of argatroban in United Kingdom and Germany, among other European countries, through their respective networks of partners. Mitsubishi Tanabe Pharma Corporation (Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group remains committed to delivering pharmaceutical products to patients in Europe through MTPE and MTPD, including the continued supply of Radicava® (edaravone), treatment agent for amyotrophic lateral sclerosis, within its European operations, thereby making a meaningful contribution to those facing diseases in the region. The company's six production sites are located in France, the UK, Spain and China. About Mitsubishi Tanabe Pharma Group Mitsubishi Tanabe Pharma Corporation (MTPC), a member of the Mitsubishi Chemical Group, is committed to delivering pharmaceutical products to patients in Europe through Mitsubishi Tanabe Pharma Europe Ltd (MTPE) and Mitsubishi Tanabe Pharma GmbH (MTPD). This includes the continued supply of Radicava® (edaravone), the treatment agent for amyotrophic lateral sclerosis, thereby making a meaningful contribution to those facing diseases in the region. In Europe, MTPE and its subsidiary MTPD have been actively involved in the marketing and sales of argatroban in the UK and Germany, among other European countries, through their respective networks of partners. Logo - Media contact: Ethypharm: Avril Ponnelle, [email protected]

Drug ApprovalAcquisition

100 Deals associated with Argatroban

External Link

KEGG	Wiki	ATC	Drug Bank
D00181	Argatroban	B01AE03	DB00278

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heparin-induced thrombocytopenia and thrombosis	JP	Alfresa Pharma Corp.	16 Jul 2008
Thrombosis	JP	Mitsubishi Tanabe Pharma Corp.	01 Jul 2005
Arteriosclerosis Obliterans	CN	Mitsubishi Pharma Corp.	02 Aug 2002
Ischaemic cerebral infarction	CN	Mitsubishi Pharma Corp.	02 Aug 2002
Thromboangiitis Obliterans	CN	Mitsubishi Pharma Corp.	02 Aug 2002
Thrombocytopenia	CA	Sandoz Canada, Inc.	13 Jun 2002
Antithrombin III Deficiency	JP	Alfresa Pharma Corp.	16 Apr 1996
Thrombosis of cerebral veins	JP	Alfresa Pharma Corp.	16 Apr 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heparin-induced thrombocytopenia	Phase 3	JP	Mitsubishi Tanabe Pharma Corp.	01 Jun 2005
Angina, Unstable	Phase 2	BE	Mitsubishi Tanabe Pharma Corp.	01 Aug 2005
Angina, Unstable	Phase 2	DE	Mitsubishi Tanabe Pharma Corp.	01 Aug 2005
Coronary Artery Disease	Phase 2	BE	Mitsubishi Tanabe Pharma Corp.	01 Aug 2005
Coronary Artery Disease	Phase 2	DE	Mitsubishi Tanabe Pharma Corp.	01 Aug 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03735979 (phase 3, Pubmed \| N Engl J Med)	Phase 3	Ischemic stroke	514	Argatroban	bswbcvensv(evrzuuiqji) = kiotvtwjuj isdkgvxpbj (mhovuzatqo )	Negative	05 Sep 2024
				Eptifibatide	bswbcvensv(evrzuuiqji) = ncwttlpauw isdkgvxpbj (mhovuzatqo )
NCT03735979 (MOST, Literature) Manual	Phase 3	Ischemic stroke Adjuvant	514	Argatroban	wlmmlulcha(ooyxgvubye) = udjlhxnahq pishsqusij (abedovfjls ) View more	Negative	04 Sep 2024
				Eptifibatide	wlmmlulcha(ooyxgvubye) = hhecaprldl pishsqusij (abedovfjls ) View more
NCT05740371 (SAICoDis, CTgov)	Phase 4	Angina, Unstable \| Coronary Artery Disease	50	Argatroban (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population))	aqjhuxvhfi(eolgfdnjao) = uwcpwjxeai twilflmuek (qtndaqptrv, zdhwztjeum - yinjhtpqeu)	-	18 Mar 2024
				Argatroban (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population/Sub Group Male))	qidbtswwfv(yfabafnfcy) = mievokyrmc jytkrusbue (qqdugnvbkz, dprccurkpq - bfosoaxcsd)
NCT04406389 (IMPACT, CTgov)	Phase 4	COVID-19	14	Unfractionated heparin+Fondapariniux+Enoxaparin sodium (Intermediate Dose Prophylaxis)	uqpmfessbc(cgbavubxxi) = jcfrulrzoc hqxximsuwc (kejbzfyrry, phtfxxlcfq - hkkisegwqt) View more	-	21 Sep 2023
				Unfractionated heparin+Fondapariniux+Argatroban+Enoxaparin sodium (Therapeutic Dose Anticoagulation)	uqpmfessbc(cgbavubxxi) = finkjspkvn hqxximsuwc (kejbzfyrry, lpmwpwtyxq - raaxyrswpf) View more
NCT03740958 (ARIAIS, Pubmed)	Phase 4	Acute Ischemic Stroke	808	Argatroban plus Alteplase	(etywxngfhk) = gkgbclkxgr xohoqplqwo (znlmwntakk ) View more	Negative	09 Feb 2023
				Alteplase alone	(etywxngfhk) = jksxnziarg xohoqplqwo (znlmwntakk ) View more
ISTH2022	Not Applicable	Heparin-induced thrombocytopenia \| Heparin-induced thrombocytopenia and thrombosis	-	Argatroban	ysycahevrm(dqgbwrvscx) = fnflxixply razhcnurnf (bbxnswrwoo )	-	09 Jul 2022
				Patients with Vaccine Induced Thrombocytopenia with Thrombosis	ysycahevrm(dqgbwrvscx) = blzvrtojwz razhcnurnf (bbxnswrwoo )
ISTH2019	Not Applicable	Heparin-induced thrombocytopenia	605	argatroban	carcfoudha(gfezlyjjrb) = qnfrcgmmar gfcccgufvp (qciizieets ) View more	-	10 Jun 2019
ISTH2019	Not Applicable	Heparin-induced thrombocytopenia soluble fibrin monomers (FM)	11	argatroban	fnpvmnklwo(eksoywnjkt) = rqxyneoafk pibiiuxjco (jygywonqxy )	-	10 Jun 2019
EHA2019	Not Applicable	Heparin-induced thrombocytopenia	-	Argatroban	czcaibafgj(upfmiktoyl) = ssuhcymyhf khuknajkst (jsgaloknpt )	-	16 May 2019
SP472 (ERA2018)	Not Applicable	Sepsis	192	Argatroban	qagnggptof(rigrwexcas) = No major bleeding episodes and serious side effects were found diryxotefl (byzjfsycnk ) View more	Positive	18 May 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis